
Bicara Therapeutics Unveils Encouraging Phase 1-1b Results of Ficerafusp-Alfa in Advanced Anal Canal Squamous Cancer at ASCO Gastrointestinal Cancers Symposium
Bicara Therapeutics Announces Encouraging Data for Ficerafusp Alfa in Combination with Pembrolizumab for Second Line Anal Cancer Bicara Therapeutics, a clinical-stage biopharmaceutical company, recently presented data from the Phase 1/1b dose expansion cohort of their investigational therapy, ficerafusp alfa, in combination with pembrolizumab for patients with second line (2L) or later squamous cancer of the…